

**CURRICULUM VITAE E ATTIVITA' SCIENTIFICA  
DOTT. CLAUDIO GASPERINI**

**Dipartimento Neuroscienze  
Azienda Ospedaliera S Camillo-Forlanini Roma**

Roma 8 aprile 2019

**Dati Anagrafici**

Nato a Riano (Roma) il 2/2/1962.

Residente in Roma Via Bagnone 27, CAP 00139

**Posizione:**

**Dirigente Medico Azienda Ospedaliera S Camillo Forlanini dal 1999**

**Abilitazione Nazionale a Professore di II Fascia dal 2012**

**Abilitazione Nazionale a Professore di I Fascia dal 2016**

**Formazione**

**1982** - Diploma di Maturita' Scientifica conseguito presso il Liceo "G Piazzi" di Morlupo (Roma).

**1989** - Laurea in Medicina e Chirurgia presso l'Universita' degli Studi di Roma "La Sapienza", con votazione 110/110 e lode e tesi sperimentale su "Fattori Prognostici dell'Ictus in Fase Acuta", relatore Prof. Cesare Fieschi.

**1989** - Abilitazione all'esercizio della professione medica.

**1992** Vincitore di borsa di studio della fondazione Cenci Bolognetti per progetto sul ruolo delle Heat shock proteins nella Sclerosi Multipla.

**1993** - Diploma di Specializzazione in Neurologia presso il Dipartimento di Neuroscienze dell'Universita' "La Sapienza di Roma" con votazione 70/70 e lode e tesi su " Studio controllato su potenziali fattori di rischio nella comparsa di esacerbazioni in pazienti affetti da Sclerosi Multipla).

**1993.** Vincitore di borsa di studio della Associazione Sclerosi Multipla Italiana per progetto di utilizzo di nuove tecniche quantitative di RMN nella SM

**1991-2004-** Docente di Neurologia Riabilitativa presso la scuola di Terapia della Riabilitazione dell'Ospedale Carlo Forlanini di Roma.

**Dal 1996-98** - Consulente Neurologo presso il Centro di Sclerosi Multipla dell'Ospedale S Camillo reparto Lancisi.

**1998** - Titolo di Dottore di Ricerca presso il Dipartimento di Neuroscienze dell'Universita' "La Sapienza" di Roma.

**Dal 1999** Dirigente Medico I Livello presso il Dipartimento di Neuroscienze Azienda Ospedaliera S Camillo Forlanini di Roma

**1999** - Coordinatore nel progetto di ricerca finanziato dalla Associazione Italiana Sclerosi Multipla: Effetto del trattamento con Interferon Beta sulla evoluzione della atrofia cerebrale in pazienti con SMRR.

**2000** Master di Farmacoeconomia sanitaria presso L'universita' Tor Vergata di Roma coordinato dal Prof Spandonaro

**2001** Master di Management Sanitario presso L' Universita' "Luiss" di Roma

**2000-2012** Coordinatore e Principal investigators di numerosi Trial clinici Nazionali ed Internazionali

**2006-2008** Docente Presso la II Facolta' della Scuola di Specializzazione in Neurologia Dell'Ospedale S Andrea Universita' La Sapienza Di Roma

**Dal 2008:** Docente Presso la I Facolta' della Scuola di Specializzazione in Neurologia Dell'Ospedale Policlinico Umberto I di Roma Universita' La Sapienza Di Roma

**Dal 2008:** Membro Di una Task Force Europea per progetto Comunita' Europea sulla ottimizzazione (MAGNIMS) dell'uso della RMN nella Sclerosi Multipla

**2009 - 2015** Membro del Consiglio Direttivo Nazionale della Societa' dei Neurologi Ospedalieri (SNO)

**2008-2018:** Tutor e Responsabile Scientifico di un gruppo di ricerca di giovani neurologi italiani nell'ambito di attivita' di ricerca nella sclerosi multipla (RIREMS)

**2012-2018** : Co-Responsabile scientifico con il Prof F Spandonaro (Facolta' di Farmacoeconomia Tor Vergata) di evento nazionale sul Management Sanitario dal titolo: L'evoluzione dei ruoli professionali in Sanita': nuove competenze del clinico nel nuovo contesto del SSN

### **Soggiorni all'estero ed incarichi internazionali**

**1993** - Soggiorno di studio di un anno presso "The NMR research group of Multiple Sclerosis - Institute of Neurology - National Hospital of London diretto dal Prof. Ian McDonald.

**1996-2018** - Membro di un gruppo di ricerca della Comunita' Europea nell'ambito di studi multicentrici sulla ottimizzazione dell'uso della RMN nella Sclerosi Multipla (MAGNIMS).

**1998 - 2018** Membro di una Task Force Europa-Stati Uniti sull'uso della RMN nella Sclerosi multipla.

**2000-2018** –Principal investigators di numerosi Trial clinici di Fase II e III Internazionali

**2009-2018:** Referee di riviste scientifiche internazionali quali : Neurology, Annals of Neurology, Multiple Sclerosis, J of Neurology-Psychiatry-Neurosurgery, European Journal of Neurology, Expert opinion in Neurology,

**2013-2018:** Membro di Editorial Board della rivista internazionale BMC Neurology

## **ATTIVITA' SCIENTIFICA**

L'attività scientifica del Dott. Gasperini è documentata da oltre 180 pubblicazioni a carattere di stampa. (libri, abstract, articoli)

Di queste 166 pubblicate su riviste straniere con elevato impact factor

Relatore in numerosi congressi nazionali ed internazionali.

Particolari campi di interesse riguardano lo studio delle malattie cerebrovascolari, degenerative e della sclerosi multipla.

Per quanto riguarda le malattie cerebrovascolari, particolare attenzione è stata rivolta agli aspetti terapeutici e radiologici e alle conseguenti implicazioni prognostiche.

Nella sclerosi multipla importanza è stata rivolta alla valutazione epidemiologica, diagnostica e terapeutica della malattia. Inoltre è stato approfondito l'aspetto patogenetico della storia naturale della malattia utilizzando tecniche qualitative e quantitative di RMN.

Il dott. Gasperini ha inoltre partecipato a numerosi Convegni Nazionali e Internazionali ed è stato principal investigator di numerosi trials clinici nazionali ed internazionali

## **Collaborazioni Scientifiche con L'Italia e con l'Estero**

- The NMR research group of Multiple Sclerosis - Institute of Neurology - National Hospital of London diretto dal Prof. Ian McDonald – D Miller – A Thompson
- The Neurologische Universitats-Poliklinik und Abteilung Neuroradiologie, Kantonsspital, Basel, Switzerland diretto dal Prof Kappos.
- The Afdeling Radiodiagnostiek, Vrje Universiteit, Amsterdam, The Netherlands diretto dal Dr Barkhof.
- Dipartimento di neurologia Ospedale S Raffaele di Milano diretto dal Prof Comi.
- Universita' La Sapienza di Roma
- Universita' Pavia
- Universita' Genova
- Universita' Siena

## SELECTED PAPERS

### **1991**

1. **Gasperini C**, Pozzilli C, Bernardi S. Irreversible total blindness in Multiple Sclerosis. Italian Journal of Neurological Sciences. 1991;12:329

### **1993**

2. Pozzilli C, **Gasperini C**, Anzini A, Grasso MG, Ristori G, Fieschi C. Anatomical and Functional correlates of cognitive deficit in Multiple Sclerosis. J. Neurol. Sci. 115 .S55-S58, 1993.

### **1994**

3. Bastianello S, Pozzilli C, D'Andrea F, Millefiorini E, Trojano M, Morino S, **Gasperini C**, Bozzao A, Gallucci M, Andreula C, Bozzao L, Gambi D, Prencipe M. A controlled trial of Mitoxantrone in Multiple Sclerosis: Serial MRI evaluation at one year. Can. J. Neurol. Sci. 1994; 21:266-270.

4. Fieschi C, **Gasperini C**, Ristori G, Bastianello S, Girmenia F, Leuzzi V, Buttinelli C, Pozzilli C, Rasura M. Diagnostic problems in "clinically definite" multiple sclerosis patients with normal CSF and multiple MRI abnormalities. European Journal of Neurology 1994; 1:127-133.

### **1995**

5. De Castro S, Cartoni D, Millefiorini E, Funaro S, **Gasperini C**, Morino S, Tallarico D, Beni S. Non-invasive assessment of Mitoxantrone cardiotoxicity in relapsing remitting Multiple Sclerosis. J. of Clinical Farmacology 1995; 35: 627-632.

6. Fieschi C, **Gasperini C**, Ristori G, Bastianello S, Girmenia F, Leuzzi V, Buttinelli C, Rasura M. Patients with clinically definite multiple sclerosis, white matter abnormalities on MRI, and normal CSF: if not multiple sclerosis, what is it? J. of Neurol, Neurosurg. and Psychiatry. 1995; 58 (2): 255-256.

7. **Gasperini C**, Grasso MG, Fiorelli M, Millefiorini E, Morino S, Anzini A, Colleluori A, Salvetti M, Buttinelli C, Pozzilli C. A controlled study of potential risk factors preceding exacerbation in Multiple Sclerosis. J. of Neurol, Neurosurg. and Psychiatry. 1995; 59:303-305.

8. Pozzilli C, Bastianello S, Koudriavtseva T, **Gasperini C**, Bozzao A, Galgani S, Paolillo A, Millefiorini E, Buttinelli C, Pierciaccante G, Piazza G, Bozzao L, Fieschi C. Human recombinant interferon beta (rebif) in the treatment of relapsing-remitting multiple sclerosis. Multiple Sclerosis 1995 1, S28-S31.

### **1996**

9. Koudriavtseva T, Pozzilli C, De Biasi C, Iannilli M, Trasimeni G, **Gasperini C**, Argentino C, Gualdi GF. High dose contrast-enhanced MRI in multiple sclerosis. Neuroradiology 1996, 38:S5-S9.

**10. Gasperini C**, Bastianello S, Ristori G, Paolillo A, Giugni E, Colonnese C, Fieschi C, Bozzao L. MRI in the differential diagnosis of multiple sclerosis without CSF abnormalities. International Journal of Neuroradiology; 1996; 2:117-122.

**11. Gasperini C**, Horsfield MA, Thorpe J, Kidd D, Barkers GJ, Tofts PS, MacManus DG, Thompson AJ, Miller DH, McDonald WI. MRI Texture in normal appearing white matter of MS patients: relationship to other quantitative MRI and clinical parameters. JMRI 1996; 6:580-584.

**12. Pozzilli C**, Bastianello S, Koudriavtseva T, **Gasperini C**, Bozzao A, Millefiorini E, Galgani S, Buttinelli C, Pierciaccante G, Piazza G, Bozzao L, Fieschi C. Magnetic resonance imaging and clinical activity before and after treatment with human recombinant beta interferon: a short term study in relapsing remitting multiple sclerosis. J. of Neurol, Neurosurg. and Psychiatry. 1996; 61:251-258.

### 1997

**13. Gasperini C**, Pozzilli C, Bastianello S, Koudriavtseva T, Thompson AJ, Horsfield MA, Colleluori A, Millefiorini E, Piazza G, Bozzao L, Fieschi C. The influence of clinical relapse and steroid therapy on development of Gd-enhancing lesions: a longitudinal MRI study in relapsing remitting multiple sclerosis. Acta Neurol Scand 1997; 95:201-207.

**14. Koudriavtseva T**, Thompson AJ, Fiorelli M, **Gasperini C**, Bastianello S, Paolillo A, Pisani A, Bozzao A, Galgani S, Pozzilli C. Gd-enhanced baseline MRI predicts clinical and MRI disease activity in relapsing remitting multiple sclerosis. J. of Neurol, Neurosurg. and Psychiatry. 1997; 62:285-287.

**15. E Millefiorini, C Gasperini, C Pozzilli, F D'Andrea, S Bastianello, M Trojano, S Morino, V Brescia Morra, A Bozzao, A Calo', ML Bernini, D Gambi, M Prencipe.** Randomized double-blind placebo controlled trial of Mitoxantrone in relapsing remitting multiple sclerosis: 24 month clinical and MRI results. J of Neurology 1997; 244: 153-159.

**16. S Bastianello, A Bozzao, A Paolillo, E Giugni, C Gasperini, T Koudriavtseva, E Millefiorini, MA Horsfield, C Colonnese, D Toni, M Fiorelli, C Pozzilli, L Bozzao.** Fast Spin-echo and Fast Flair sequences versus conventional spin echo for quantification of multiple sclerosis. AJMR 1997; 18: 699-704.

**17. F Giubilei, S Bastianello, A Paolillo, C Gasperini, et al.** Quantitative magnetic resonance analysis in vascular dementia. J of Neurology 1997; 244: 246-251.

**18. E Giugni, C Pozzilli, S Bastianello, C Gasperini, A Paolillo, T Koudriavtseva, M Frontoni, D Farina, L Bozzao.** MRI measure and their relations with clinical disability in relapsing remitting and secondary progressive multiple sclerosis. Multiple Sclerosis 1997; 3: 221-225.

**19. M Filippi, JH Waesberghe, MA Horsfield, S Bressi, C Gasperini, TA Yoursry, ML Gawne-Cain, SP Morrissey, MA Rocca, F Barkhof, GJ Lycklama A Nijeholt, S Bastianello, DH Miller.** Interscanner variation in brain MRI lesion load measurements in MS: Implications for clinical trials. Neurology 1997; 49: 371-377.

**20. C. Gasperini.** Differential diagnosis in Multiple Sclerosis. Int. MS Journal. 1997 Vol. 4 No 1.

21. C Colosimo, C Pozzilli, M Frontoni, D Farina, T Koudriavtseva, **C Gasperini**, M Salvetti, G Valesini. No increase of serum autoantibodies during therapy with recombinant human interferon Beta 1a in relapsing remitting multiple sclerosis. Acta Neurol Scand. 1997. 96: 372-374.
22. Giubilei F, Sarrantonio A, Tisei P, **Gasperini C**, Salvetti M. Four-year follow-up of a case of acute multiple sclerosis of the Marburg type. Ital. J. Neurol. Sci. 1997: 18: 163-166.

## 1998

23. **C Gasperini**, C Pozzilli, S Bastianello, T Koudriavtseva, S Galgani, E Millefiorini, A Paolillo, MA Horsfield, L Bozzao, C Fieschi. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. Neurology 1998; 50 (2): 403-405.
24. G Antonelli, F Bagnato, C Pozzilli, E Simeoni, S Bastianello, M Currenti, C Fieschi, **C Gasperini**, M Salvetti, F Dianzani. Development of Neutralizing Antibodies in patients with Relapsing Remitting Multiple Sclerosis treated with Interferon Beta 1a. J Interferon Research 1998 .
25. G Ristori, F Laurenti, P Stacchini, **C Gasperini**, C Buttinelli, C Pozzilli, M Salvetti. Serum Amyloid A protein is elevated in Relapsing Remitting Multiple Sclerosis. J Neuroimmunology 1998 in press
26. T Koudriavtseva, C Pozzilli, M Fiorelli, C Gasperini, F Bagnato, S Galgani, M Frontoni, O Ciccarelli, S Bastianello. Determinants of Gd-enhanced MRI response to IFNB 1a treatment in relapsing remitting multiple sclerosis. Multiple Sclerosis 1998 .
- 27 M Filippi, ML Gawne-Cain, **C Gasperini**, JH van Waesberghe, J Grimaud, H Ader, F Barkhof, MP Sormani, DH Miller. The effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology 1998 50: 230-237.
28. PD Molineaux, M Filippi, F Barkhof, **C Gasperini**, T Yousry, L Truyen HM Lai, MA Rocca, OF Moseley, DH Miller. Correlation between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis: a multicentre longitudinal study. Ann Neurol 1998 43 (3): 332-339
29. M Filippi, G Mastronardo, S Bastianello, MA Rocca, M Rovais, **C Gasperini**, C Pozzilli, G Comi. A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. J Neurol Sciences 1998
30. M Filippi, M Rovaris, R Capra, **C Gasperini**, TA Yousry, MP Sormani, F Prandini, V Martinelli, S Bastianello, I Kuhne, C Pozzilli, G Comi. A multicentre longitudinal study comparing the sensitivity of monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: implications for phase II clinical trials. Brain
31. M Filippi, M Rovaris, **C Gasperini**, R Capra, S Bastianello, I Kuhne, TA Yousry. A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis. Journal of Neuroimaging 1998; 8 (2): 88: 93
32. S Bastianello, **C Gasperini**, A Paolillo, E Giugni, O Ciccarelli, MP Sormani, M Rovaris, C

Pozzilli, M Filippi. A longitudinal study evaluating the sensitivity of enhanced MR in multiple sclerosis: effect of gadolinium dose and magnetization transfer contrast. AJMR 1998

33. C Pozzilli, S Bastianello, **C Gasperini**, M Salvetti. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 1998.

34. M Filippi, G Mastronardo, MA Rocca, R Capra, **C Gasperini**, M Rovaris, S Bastianello, G Comi. Detecting new lesion formation in multiple sclerosis: the relative contributions of monthly dual-echo and T1 weighted scans after triple dose gadolinium. European Neurology 1998,

35. M Rovaris, G Matronardo, **C Gasperini**, F Prandini, TA Yousry, M Filippi. MRI evolution of new MS lesions enhancing after different doses of gadolinium. Acta Neurol Scand 1998

## 1999

36. A Paolillo, S Bastianello, M Frontoni, **C Gasperini**, E Giugni, O Ciccarelli, F Bagnato, T Koudriatseva, C Pozzilli. Magnetic resonance imaging outcome of new enhancing lesions in multiple sclerosis patients treated with rIFN $\beta$  1a. J of Neurology 1999; 246 (6):443-8.

37. M Filippi, M Rovaris, S Bastianello, **C Gasperini**, D Origgi, P Reganati, C Pozzilli, G Comi. A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. J of Neurology 1999; 246 (2): 97-106

38. Sormani MP, Bruzzi P, Miller DH, **Gasperini C**, Barkhof F, Filippi M. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci 1999; 163 (1):74-80.

39. Kappos L, Moeri D, Radue EW, Schoetzau A, Schwikert K, Barkhof F, Miller DH, Guttmann CR, Weiner HL, **Gasperini C**, Filippi M. Predictive value of gadolinium enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999; 353 (9157): 964-9.

40. Sormani MP, Molineux PD, **Gasperini C**, Barkhof F, Yousry TA, Miller DH, Filippi M. Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results. J Neurol Neurosurg Psychiatry 1999; 66 (4): 465-9

41. Poggi A, Zocchi MR, Costa P, Ferrero E, Borsellino G, Placido R, Galgani S, Salvetti M, **Gasperini C**, Ristori G, Brosnan CF, Battistini L. IL-12 mediated NKRP1A up-regulation and consequent enhancement of endothelial transmigration of V delta 2+ TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients. J Immunol 1999; 162 (7): 4349-54.

42. Mainero C, Faroni J, **Gasperini C**, Filippi M, Giugni E, Ciccarelli O, Rovaris M, Bastianello S, Comi G, Pozzilli C. Fatigue and magnetic resonance imaging activity in multiple sclerosis. J Neurol 1999; 246 (6): 454-8.

43. Ciccarelli O, Giugni E, Paolillo A, Mainero C, **Gasperini C**, Bastianello S, Pozzilli C. Magnetic resonance outcome of new enhancing lesions in patients with relapsing remitting multiple sclerosis. Eur J Neurol 1999; 6 (4): 455-9.

44. Filippi M, Rovaris M, Capra R, **Gasperini C**, Prandini F, Martinelli V, horfield MA, Bastianello

S, Sormani MP, Pozzilli C, Comi G. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. J Neurol Neurosurg Psychiatry 1999; 67 (3): 386-9

45. Tortorella C, Codella M, Rocca MA, **Gasparini C**, Capra R, Bastianello S, Filippi M. Disease activity in multiple sclerosis studied by weekly triple dose magnetic resonance imaging. J Neurol 1999; 246 (8): 689-92.

46. Ristori G, Montesperelli C, **Gasparini C**, Battistini L, Borsellino G, Buttinelli C, Cannoni S, Perna A, Pozzilli C, Salvetti M. T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis. J Neuroimmunol 1999; 99 (1):91-6.

47. Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, Di Marco P, **Gasparini C**, Fieschi C, Dianzani F. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta -1b. J Neurol Sci. 1999; 168 (2): 131-6.

48. Rovaris M, Barkhof F, Bastianello S, **Gasparini C**, Tubridy N, Yousry TA, Sormani MP, Viti B, Miller DH, Filippi M. Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. J Neurol 1999; (10):920-5.

49. **Gasparini C**, Pozzilli C, Bastianello S, Giugni E, Horsfield MA, Koudriavtseva T, Galgani S, Paolillo A, Haggiag S, Millefiorini E, Fieschi C. Interferon Beta 1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images. J Neurol Neurosurg Psychiatry 1999; 67 (5): 579-84

50. Rovaris M, Capra R, Martinelli V, **Gasparini C**, Prandini F, Pozzilli C, Comi G, Filippi M. Cumulative effect of weekly low dose of interferon beta 1a on standard and triple dose contrast enhanced MRI from multiple sclerosis patients. J Neurol Sci 1999; 171 (2): 130-4.

51. Filippi M, Rocca MA, **Gasparini C**, Sormani MP, Bastianello S, Horsfield MA, Pozzilli C, Comi G. Interscanner variation in brain MR lesion load measurement in multiple sclerosis using conventional spin-echo rapid relaxation-enhanced, and fast FLAIR sequences. AJNR. 1999; 20 (1):133-7.

## 2000

52. Bagnato F, Tancredi A, Richert N, **Gasparini C**, Bastianello S, Bash C, McFarland H, Pozzilli C, Frank JA. Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study. Multiple Sclerosis 2000; 6(1):43-9.

53. Molyneaux PD, Miller DH, Filippi M, Yousry T, Kappos L, **Gasparini C**, Ader HJ, Barkhoff F. The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement. J Neurol. 2000; 247(1): 34-40.

54. Paolillo A, Pozzilli C, **Gasparini C**, Giugni E, Mainero C, Giuliani S, Tomassini V, Millefiorini E, Bastianello S. Brain atrophy in relapsing remitting multiple sclerosis: relationship with "black holes", disease duration and clinical disability. J Neurol Sci. 2000; 174(2): 85-91.

55. Borsellino G, Koul O, Placido R, Tramonti D, Luchetti D, Galgani S, Salvetti M, **Gasparini C**,

Ristori G, Bonetti B, Bach S, Cipriani B, Battistini L.  
Evidence for a role of gamma delta T cells in demyelinating diseases as determined by activation states and response of lipid antigens. J Neuroimmunology 2000; 107(2): 124-9.

**56.** Bastianello S, Paolillo A, Giugni E, Giuliani S, Evangelisti G, Luccichenti G, Angeloni U, Colonnese C, Salvetti M, **Gasparini C**, Pozzilli C, Fieschi C.  
MRI of spinal cord in MS. J Neurovirology 2000; Suppl 2: S130-3.

**57.** Ciccarelli O, Bagnato F, Mainero C, Salvetti M, Paolillo A, **Gasparini C**, Bastianello S, Pozzilli C.  
Antinuclear antibodies and responses to IFN beta-1a treatment in relapsing remitting multiple sclerosis. Mult. Scler. 2000; 6(3): 137-9.

**58.** **Gasparini C**, Paolillo A, Rovaris M, Yousry TA, Capra R, Bastianello S, Filippi M.  
A comparison of the sensitivity of MRI after double-triple dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. Magn Reson Imaging 2000; 18(6): 761-3.

**59.** Ristori G, Giubilei F, Giunti D, Perna A, **Gasparini C**, Buttinelli C, Salvetti M, Uccelli A.  
Myelin basic protein intramolecular spreading without progression in a patient with multiple sclerosis. J Neuroimmunology. 2000; 110(1-2): 240-3.

**60.** Yousry I, Filippi M, Walther E, **Gasparini C**, Capra R, Yousry TA.  
Serial gadolinium DTPA of spinal cord MRI in multiple sclerosis: triple vs single dose. Magn Reson Imaging. 2000; 18(9): 1183-6.

## 2001

**61.** **Gasparini C**, Rovaris M, Sormani MP, Bastianello S, Pozzilli C, Comi G, Filippi M.  
Intra-observer inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. Mult Scler. 2000; 7(1):27-31

**62.** Solaro C, Uccelli MM, Bricchetto G, **Gasparini C**, Mancardi G.  
Topiramate relieves idiopathic and symptomatic trigeminal neuralgia. J Pain Symptom Manage 2001; 21(5):367-8.

**63.** **Gasparini C.**  
Differential diagnosis in multiple sclerosis. Neurol Scien. 2001; 22:93-7.

## 2002

**64.** Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomasini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dalkhe F, **Gasparini C.**  
Monthly corticosteroids decrease neutralizing antibodies to interferon beta 1b: a randomized trial in multiple sclerosis. J Neurol 2002; 249:50-56.

**65.** **Gasparini C**, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.  
MRI brain volume changes in relapsing multiple sclerosis patients treated with Interferon Beta 1a. Mult Scler. 2002; 8(2): 119-23.

**66.** Bagnato F, Pozzilli C, Scagnolari C, Bellomi F, Pasqualetti P, **Gasparini C**, Millefiorini E,

Galgani S, Spadaro M, Antonelli G. A one year study on the pharmacodynamic profile of Interferon Beta 1a in MS. Neurology 2002; 58(9):1409-11.

67. Giannelli G, De Marzo A, Scagnolari C, Bergamini C, Fransvea E, Bagnato F, Bellomi F, Millefiorini E, **Gasparini C**, Antonaci S, Antonelli G. Proteolytic balance in patients with multiple sclerosis during Interferon Beta treatment. J Interferon Cytokine Res. 2002; 22(6):689-92.

68. Pozzilli C, Brunetti M, Amicosante AM, **Gasparini C**, Ristori G, Palmisano L, Battaglia M. Home based management multiple sclerosis: results of a randomised controlled trial. J Neurol, Neurosurg, Psychiatry 2002; 73(3):250-5.

69. Paolillo A, Pozzilli C, Giugni E, Tomassini V, **Gasparini C**, Fiorelli M, Maniero C, Horsfield M, Galgani S, Bastianello S, Pozzilli C. A 6 years clinical and MRI follow-up study of patients with relapsing remitting MS treated with Interferon Beta. Eur. J Neurol 2002; 9(6): 645-55.

## 2003

70. Pozzilli C, Tomassini V, Marinelli F, Paolillo A, **Gasparini C**, Bastianello S. 'Gender gap' in multiple sclerosis: magnetic resonance imaging evidence. Eur J Neurol 2003; 10(1):95-7

71. Battistini L, Piccio L, Rossi B, Bach S, Galgani S, **Gasparini C**, Ottoboni L, Ciabibi D, Caramia MD, Bernardi G, Laudanna C, Scarpini E, McEver RP, Butcher EC, Borsellino G, Constantin G. CD8+ T cells from patients with acute multiple sclerosis displays selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 2003; 101: 4775-82.

72. Bellomi F, Scagnolari C, Tomassini V, **Gasparini C**, Paolillo A, Pozzilli C, Antonelli G. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol. Sci. 2003; 215:3-8.

## 2004

73. Pozzilli C, Palmisano L, Mainiero C, Tomassini V, Marinelli F, Ristori G, **Gasparini C**, Fabiani M, Battaglia MA. Relationship between emotional stress in caregivers and health status in person with MS. Mult Scler. 2004; 10: 442-6.

74. Solaro C, Bricchetto G, Amato MP, Cocco E, Colombo B, D'Aleo G, **Gasparini C**, Ghezzi A, Martinelli V, Milanese C, Patti F, Trojano M, Verdun E, Mancardi GL, PaIMS study group. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 2004;14:919-21.

## 2005

75. Lolli F, Mazzanti B, Pazzagli M, Peroni E, Alcaro MC, Sabatino G, Lanzillo R, Brescia Morra V, Santoro L, **Gasparini C**, Galgani S, D'Elia MM, Zipoli V, Sotgiu S, Pugliatti M, Rovero P, Chelli M, Papini AM. The glycopeptide CSF114 (GLc) detects serum antibodies in multiple sclerosis. J Neuroimmunol. 2005; 167 (1-2):131-7

## 2006

76. Tomassini V, Paolillo A, Russo P, Prosperini L, **Gasparini C**, Antonelli G, Bastianello S, Pozzilli C. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol. 2006 ; 253 (3): 287-93

## 2007

77. Bodini B, Mandarelli G, Tomassini V, Tarsitani L, Pestalozza I, **Gasparini C**, Lenzi GL, Cancheri P, Pozzilli C. Alexithymia in multiple sclerosis: relationship with fatigue and depression. Acta Neurol Scand. 2007: Dec 19.

## 2008

78. Lugaresi A, Durastanti V, **Gasparini C**, Lai M, Pozzilli C, Orefice G, Sotgiu S, Pucci E, Ardito B, Millefiorini E, CoSa study Group. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. Clin Neuropharmacol. 2008 May-Jun;31(3):167-72.

79. De Stefano N, Filippi M, Hawkins C; 9011 study group. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2008 Mar 15;266(1-2):44-50.

80. Centonze D, Furlan R, **Gasparini C**, Salvetti M, Battistini L. Early relapses after the first dose of Natalizumab in active multiple sclerosis patients. Multiple Sclerosis 2008 Sep 14 (8) : 1137-1138

81. **Gasparini C**, Cefaro LA, Borriello G, Tosto G, Prosperini L, Pozzilli C. Emerging oral drugs for multiple sclerosis. Expert Opin. Emerg Drugs. 2008 Sep 13(3): 465-77. Review

## 2009

122. COGIMUS study group. Cognitive impairment and its relation with disease measures in mildly disabled patients with RRMS. Baseline results from COGIMUS Study. Multiple Sclerosis 2009 Jul 15 (7): 779-88.

123. D'Arena G, **Gasparini C**, Cascavilla N. Long lasting response of chronic lymphocytic leukemia and multiple sclerosis in a patient treated with oral fludarabine alone. Tumori 2009 May-Jun 95 (3): 406-7

124. **Gasparini C**, Ruggieri S. New oral drugs for multiple sclerosis. Neurol Sci. 2009 Oct;30 Suppl 2:S179-83. Review

125. Sbardella E, Tomassini V, **Gasparini C**, Bellomi F, Cefaro LA, Morra VB, Antonelli G, Pozzilli C. Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study. BMC Neurol.

2009 Oct 13;9:54.

**126.**Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group. Effect of glatiramer acetate on conversion to clinically isolated syndrome (preCISe study: a randomised double – blind, placebo – controlled trial. *Lancet*. 2009 Oct 31;374(9700):1503-11.

**127.**Bergamaschi R, Rezzani C, Minguzzi S, Amato MP, Patti F, Marrosu MG, Bonavita S, Grasso MG, Ghezzi A, Rottoli M, **Gasparini C**, Restivo D, Maimone D, Rossi P, Stromillo ML, Montomoli C, Solaro C, Group D. Validation of the Dymus questionnaire for the assessment of dysphagia in multiple sclerosis. *Funct Neurol*. 2009 Jul-Sep;24(3):159-62.

## 2010

**128.** **Gasparini C**, Ruggieri S, Pozzilli C. Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets. *Ther Clin Risk Manag*. 2010 Sep 7;6:391-9.

**89.** Millefiorini E, Cortese A, Di Rezze S, Barletta G, Bellantonio P, Batocchi AP, Di Battista G, Fiore S, **Gasparini C**, Grasso MG, Koudriatseva T, Totaro R, Durastanti V. The prevalence of multiple sclerosis in central Italy. *Mult Scler*. 2010 Dec;16(12):1432-6

**90.** De Stefano N, Curtin F, Stubinski B, Blevins G, Drulovic J, Issard D, Shotekov P, **Gasparini C**; IMPROVE Study Investigators. Rapid benefits of a new formulation of subcutaneous interferon beta – 1a in relapsing remitting multiple sclerosis. *Mult Scler*. 2010 Jul;16(7):888-92.

**91.** Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group. Effects of immunomodulatory treatment with subcutaneous interferon beta -1a on cognitive decline in mildly disabled patients with relapsing remitting multiple sclerosis. *Mult Scler*. 2010 Jan;16(1):68-77.

## 2011.

**92.** De Stefano N, Stromillo ML, Rossi F, Battaglini M, Giorgio A, Portaccio E, Hakiki B, Malentacchi G, **Gasparini C**, Santangelo M, Bartolozzi ML, Sormani MP, Federico A, Amato MP. Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis . *PLoS One*. 2011 Apr 29;6(4)

**93.** Patti F, Amato M, Trojano M, Bastianello S, Tola M, Picconi O, Cilia S, Cottone S, Centonze D, **Gasparini C**. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNitive Impairment in MULTiple Sclerosis) study. *Mult Scler*. 2011 Apr 18.

94. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, **Gasperini C**, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P; the Sativex Spasticity Study Group. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols\* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis J Neurol. 2011 1468-1331.
95. Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; FORTE Study Group. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol. 2011 Jan;69(1):75-82.
96. Dalla Libera D, Di Mitri D, Bergami A, Centonze D, **Gasperini C**, Grasso MG, Galgani S, Martinelli V, Comi G, Avolio C, Martino G, Borsellino G, Sallusto F, Battistini L, Furlan R. T regulatory cells are markers of disease activity in multiple sclerosis patients. PLoS One. 2011;6(6):e21386
97. Sbardella E, Tomassini V, Stromillo M, Filippini N, Battaglini M, Ruggieri S, Ausili Cefaro L, Raz E, **Gasperini C**, Sormani M, Pantano P, Pozzilli C, De Stefano N. Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2011 Jul 5.
98. Pantano P, Bernardi S, Tinelli E, Pontecorvo S, Lenzi D, Raz E, Tona F, **Gasperini C**, Pozzilli C. Impaired cortical deactivation during hand movement in the relapsing phase of multiple sclerosis: a cross-sectional and longitudinal fMRI study. Mult Scler. 2011 Jun 15.
99. Prosperini L, Gianni C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, **Gasperini C**. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler. 2011 Aug
100. De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, **Gasperini C**. Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study. J Neurol Sci. 2011 Aug 29
101. Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, Luccichenti G, Quarantelli M, Picconi O, Patti F; COGIMUS study group. Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon  $\beta$ -1a in the COGNitive Impairment in Multiple Sclerosis (COGIMUS) study BMC Neurol. 2011 Oct 14;11:125.
102. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 Oct 6;365(14):1293-303
103. Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A,

Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, **Gasparini C**, Rodegher M, Straffi L, Ponzio M, Comi G; Italian Mitoxantrone Group Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. *Neurology*. 2011 Nov 22;77(21):1887-95

**104.** Mancardi G, Sormani M, Di Gioia M, Vuolo L, Gualandi F, Amato M, Capello E, Currò D, Uccelli A, Bertolotto A, **Gasparini C**, Lugaresi A, Merelli E, Meucci G, Motti L, Tola M, Scarpini E, Repice A, Massacesi L, Saccardi R. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. *Mult Scler*. 2011 Dec 6.

**105. Gasparini C**, Ruggieri S. Emerging oral drugs for relapsing-remitting multiple sclerosis, *Expert Opin Emerg Drugs*. 2011 Dec;16(4):697-712.

## 2012

**106.** Annovazzi P, Tomassini V, Bodini B, Boffa L, Calabrese M, Cocco E, Cordioli C, De Luca G, Frisullo G, Gallo A, Malucchi S, Paolicelli D, Pesci I, Radaelli M, Ragonese P, Roccatagliata L, Tortorella C, Vercellino M, Zipoli V, **Gasparini C**, Rodegher M, Solaro C. A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. *Neurol Sci*. 2013 Feb;34(2):197-203.

**107 Gasparini C**, Ruggieri S. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. *Drug Des Devel Ther*. 2012;6:175-86.

## 2013

**108.** Giorgio A, Battaglini M, Rocca MA, De Leucio A, Absinta M, van Schijndel R, Rovira A, Tintore M, Chard D, Ciccarelli O, Enzinger C, **Gasparini C**, Frederiksen J, Filippi M, Barkhof F, De Stefano N; MAGNIMS Study Group. Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. *Neurology*. 2013 Jan 15;80(3):234-41.

**109.** Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M; Italian MS Study Group (Ghezzi A, Zaffaroni M, Bianchi A, Pozzilli C, Prosperini L, Borriello G, Filippi M, Moiola L, Gerevini S, Rocca MA, Martinelli V, Comi G, Brescia-Morra V, Lanzillo R, Grimaldi LM, Bucello S, Lus G, Rinaldi F, Gallo P, Trojano M, Provinciali L, Pucci E, Bortolon F, Capra R, Coniglio G, **Gasparini C**, Lugaresi A, Pietrolongo E, Farina D, di Ioia M, Milani N, Rottoli MR, Sarchielli P). Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. *Mult Scler*. 2013 Jul;19(8):1106-12.

**110.** Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMPO) Trial Group (Maida E, Auff E, Fazekas F, Berger T, Bhan V,

Bouchard JP, Duquette P, Freedman M, Grand'maison F, Kremenchutzky M, Bourque C, Marrie RA, Melanson M, Patry D, O'Connor P, Oger J, Stefanelli M, Jacques F, Venegas P, Miranda M, Barrientos N, Tenhamm E, Gloger S, Rohde G, Mares J, Frederiksen J, Stenager E, Haldre S, Gross-Paju K, Elovaara I, Sumelahti ML, Erälänna JP, Erälänna JP, Färkkilä M, Harno H, Reunanen M, Jolma T, Confavreux C, Camu W, Clavelou P, Magy L, Debouverie M, Edan G, Lebrun-Frenay C, Moreau T, Pelletier J, Roullet E, Alamowitch S, Clanet M, Hautecoeur P, Damier P, Rumbach L, Chan A, Schimrigk S, Haas J, Lensch E, Diener H, Limmroth V, Anders D, Berghoff M, Oschmann P, Stangel M, Berghoff M, Frese A, Kiefer R, Marziniak M, Zettl U, Stark E, Jendroska K, Reifschneider G, Amato MP, Comi G, Cosi V, Gallo P, **Gasparini C**, Ghezzi A, Trojano M, Pozzilli C, Montanari E, Zwanikken CP, Jongen PJ, Centrum MS, Van Munster ET, Hupperts RM, Anten B, Sanders EA, Celius E, Hovdal H, Krogseth SB, Kozubski W, Kwiecinski H, Czlonkowska A, Stelmasiak Z, Selmaj K, Hasiec T, Fryze W, Drozdowski W, Kochanowicz J, Cunha L, De Sá J, Harrington Sena A, Odinak M, Skoromets A, Gusev E, Boiko A, Lashch N, Stolyarov I, Belova A, Malkova N, Doronin B, Yakupov E, Brundin L, Hillert J, Kappos L, Karabudak R, Irkec C, Idiman E, Turan O, Efendi H, Gedizlioglu M, Buchakchyyska N, Goloborodko A, Ipatov A, Kobets S, Lebedynets V, Moskovko S, Yushchenko OI, Sanotskyy Y, Smolanka V, Yavorskaya V, Bates D, Evangelou N, Hawkins C, McLean B, O'Riordan J, Price S, Turner B, Barnes D, Zajicek J, Honeycutt W, Khan O, Spikol L, Stevens J). Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. *Mult Scler*. 2013 Sep;19(10):1310-9.

111. Chiurciu V, Cencioni MT, Bisicchia E, De Bardi M, **Gasparini C**, Borsellino G, Centonze D, Battistini L, Maccarrone M. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. *Ann Neurol*. 2013 May;73(5):626-36.

112. **Gasparini C**, Ruggieri S, Mancinelli CR, Pozzilli C. Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod. *Ther Clin Risk Manag*. 2013;9:73-85.

113. Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, **Gasparini C**, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F, Battistini L. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. *PLoS Pathog*. 2013;9(4):e1003220.

114. Stromillo ML, Giorgio A, Rossi F, Battaglini M, Hakiki B, Malentacchi G, Santangelo M, **Gasparini C**, Bartolozzi ML, Portaccio E, Amato MP, De Stefano N. Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. *Neurology*. 2013 Jun 4;80(23):2090-4

115. Solaro C, Rezzani C, Trabucco E, Amato MP, Zipoli V, Portaccio E, Giannini M, Patti F, D'Amico E, Frau J, Loreface L, Bonavita S, Della Corte M, Grasso MG, Finamore L, Ghezzi A, Annovazzi P, Rottoli M, **Gasparini C**, Restivo D, Maimone D, Rossi P, Stromillo ML, Bergamaschi R. Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire). *J Neurol Sci*. 2013 Aug 15;331(1-2):94-7.

116. Kearney H, Rocca MA, Valsasina P, Balk L, Sastre-Garriga J, Reinhardt J, Ruggieri S, Rovira A, Stippich C, Kappos L, Sprenger T, Tortorella P, Rovaris M, **Gasparini C**, Montalban X, Geurts JJ, Polman CH, Barkhof F, Filippi M, Altmann DR, Ciccarelli O, Miller DH, Chard DT. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. *Mult Scler*. 2014 Jan;20(1):72-80

117. **Gasparini C**, Haggiag S, Ruggieri S. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. *Expert Opin Investig Drugs*. 2013 Oct;22(10):1243-53.

118. Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, Cottone S, Plant A, Picconi O; COGIMUS Study Group (Patti F, Lo S, Messina S, Vecchio R, Maimone D, **Gasparini C**, Orefice G, Brescia-Morra V, Florio C, Amato MP, Goretti B, Portaccio E, Zipoli V, Bertolotto A, Bramanti P, Sessa E, Centonze D, Cottone S, Salemi G, Falcini M, Gallo P, Perini P, Gigli GL, Giuliani G, Grimaldi LM, Murri L, Lugaresi A, Monaco F, Montanari E, Motti L, Neri G, Paciello M, Provinciali L, Ragno M, Rosati G, Ruggieri S, Tola MR, Caniatti L, Tonali P, Batocchi AP, Trojano M, Di Monte E, De Caro MF, Ghezzi A, Zaffaroni M, Zolo P, Zorzon M, Scarpini E, Durelli L, Carolei A, Totaro R, Spitaleri D, Tartaglione A). Subcutaneous interferon  $\beta$ -1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. *PLoS One*. 2013 Aug30;8(8):e74111.

119. Haggiag S, Ruggieri S, **Gasparini C**. Efficacy and safety of laquinimod in multiple sclerosis: current status. *Ther Adv Neurol Disord*. 2013 Nov;6(6):343-52.

## 2014

120. Ristori G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, Cecconi P, Lanzillo R, Quarantelli M, Buttinelli C, **Gasparini C**, Frontoni M, Coarelli G, Caputo D, Bresciamorra V, Vanacore N, Pozzilli C, Salvetti M. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. *Neurology*. 2014 Jan 7;82(1):41-8.

121. Camperio C, Muscolini M, Volpe E, Di Mitri D, Mechelli R, Buscarinu MC, Ruggieri S, Piccolella E, Salvetti M, **Gasparini C**, Battistini L, Tuosto L. CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes. *Immunol Lett*. 2014 Mar-Apr;158(1-2):134-42.

122. Prosperini L, Mancinelli CR, Pozzilli C, Grasso MG, Clemenzi A, Collorone S, Pontecorvo S, Francia A, Villani V, Koudriavtseva T, Buttari F, Centonze D, Di Battista G, Frisullo G, Galgani S, **Gasparini C**. From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study. *Eur Neurol*. 2014 Jan 25;71(5-6):233-241. [Epub ahead of print]

123. Frisullo G, Calabrese M, Tortorella C, Paolicelli D, Ragonese P, Annovazzi P, Radaelli M, Malucchi S, Gallo A, Tomassini V, Nociti V, D'Onghia M, Lo Re V, Rodegher M, Solaro C, **Gasparini C**. Thyroid autoimmunity and dysfunction in multiple sclerosis

patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. *Mult Scler*. 2014 Feb 10. [Epub ahead of print]

**124.** Ruggieri S, Tortorella C, **Gasperini C**. Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis. *Ther Clin Risk Manag*. 2014. Review

**125.** Amorini AM, Nociti V, Petzold A, **Gasperini C**, Quartuccio E, Lazzarino G, Di Pietro V, Belli A, Signoretti S, Vagnozzi R, Lazzarino G, Tavazzi B. Serum lactate as a novel potential biomarker in multiple sclerosis. *Biochim Biophys Acta*. 2014

**126.** Serana F, Imberti L, Amato MP, Comi G, **Gasperini C**, Ghezzi A, Martinelli V, Provinciali L, Rottoli MR, Sotgiu S, Stecchi S, Vecchio M, Zaffaroni M, Cordioli C, Capra R. MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. *PLoS One*. 2014

**127.** Totaro R, Lugaresi A, Bellantonio P, Danni M, Costantino G, **Gasperini C**, Florio C, Pucci E, Maddestra M, Spitaleri D, Lus G, Ardito B, Farina D, Rossi M, Di Carmine C, Altobelli E, Maccarone B, Casalena A, De Luca G, Travaglini D, Di Ioia M, Di Tommaso V, Fantozzi R, Ruggieri S, Provinciali L, De Riso S, Mundi C, Fuiani A, Galgani S, Ruggieri S, Maniscalco GT, Giuliani G, Cartechini E, Petretta V, Fratta M, Alfieri G, Gatto M, Carolei A; Natalizumab Long-Term Treatment Study group. Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. *Int J Immunopathol Pharmacol*. 2014

**128.** Di Battista G, Bertolotto A, **Gasperini C**, Ghezzi A, Maimone D, Solaro C. Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy's Adherence, Hospital Reliability's Perception, and Services Provided Quality. *Mult Scler Int*. 2014

## 2015

**129.** De Giglio L, **Gasperini C**, Tortorella C, Trojano M, Pozzilli C. Natalizumab discontinuation and disease restart in pregnancy: a case series. *Acta Neurol Scand*. 2015 May;131(5):336-40.

**130.** Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, **Gasperini C**, Galgani S, Solaro C, Centonze D, Bertolotto A, Pozzilli C, Ghezzi A. Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. *Mult Scler*. 2015 Feb 19.

**131.** Ruocco G, Rossi S, Motta C, Macchiarulo G, Barbieri F, De Bardi M, Borsellino G, Finardi A, Grasso MG, Ruggieri S, **Gasperini C**, Furlan R, Centonze D, Battistini L, Volpe E. T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis. *Clin Sci (Lond)*. 2015 Aug 1;129(4):291-303.

**132.** Petzold A, Nijland PG, Balk LJ, Amorini AM, Lazzarino G, Wattjes MP, **Gasperini**

C, van der Valk P, Tavazzi B, Lazzarino G, van Horssen J. Visual pathway neurodegeneration winged by mitochondrial dysfunction. *Ann Clin Transl Neurol.* 2015 Feb;2(2):140-50.

**133.** Cencioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, Ruggieri S, **Gasperini C**, Centonze D, Barilá D, Battistini L, Volpe E. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. *Cell Death Dis.* 2015

**134.** Cencioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, Ruggieri S, **Gasperini C**, Centonze D, Barilá D, Battistini L, Volpe E. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. *Cell Death Dis.* 2015

**135.** Hupperts R, Lycke J, Short C, **Gasperini C**, McNeill M, Medori R, Tofil-Kaluza A, Hovenden M, Mehta LR, Elkins J. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. *Mult Scler.* 2015 Apr 28

**136.** Di Mitri D, Sambucci M, Loiarro M, De Bardi M, Volpe E, Cencioni MT, **Gasperini C**, Centonze D, Sette C, Akbar AN, Borsellino G, Battistini L. The p38 MAPK cascade modulates TH17 differentiation and functionality in Multiple Sclerosis. *Immunology.* 2015 Jun 12

## 2016.

**137.** Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, **Gasperini C**, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F; MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis : MAGNIMS consensus guidelines *Lancet Neurol.* 2016 Mar;15(3):292-303

**138.** O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. *Neurology.* 2016 Mar 8;86(10):920-30. Erratum in: *Neurology.* 2016 Oct 4;87(14 ):1524.

**139.** Bargagli AM, Colais P, Agabiti N, Mayer F, Buttari F, Centonze D, Di Folco M, Filippini G, Francia A, Galgani S, **Gasperini C**, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Davoli M. Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. *J Neurol.* 2016 Apr;263(4):751-9.

**140.** Montanari E, Rottoli M, Maimone D, Confalonieri P, Plewnia K, Frigo M, Francia A, Pala A, Losignore NA, Ragonese P, Veneziano A; POSIDONIA study group. A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study. 2016 May 15;364:105-9.

**141.** Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, **Gasparini C**, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51.

**142.** Sormani MP, **Gasparini C**, Romeo M, Rio J, Calabrese M, Cocco E, Enzinger C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group. Assessing response to interferon Beta in a multicenter dataset of patients with MS Neurology. 2016 Jul 12;87(2):134-40.

**143.** **Gasparini C**, Hupperts R, Lycke J, Short C, McNeill M, Zhong J, Mehta LR. Prolonged release fampridine treatment improved subject reported impact of multiple sclerosis : Item-level analysis of the MSIS-29 J Neurol Sci. 2016 Nov 15;370:123-131.

**144.** Lazzarino G, Amorini AM, Petzold A, **Gasparini C**, Ruggieri S, Quartuccio ME, Lazzarino G, Di Stasio E, Tavazzi B. Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis. Mol Neurobiol. 2016 Nov 8. 3.

**145.** Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, **Gasparini C**, Millefiorini E, Mirabella M, Pozzilli C. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. J Neurol. 2016 Nov 22.

**146.** Di Bari M, Reale M, Di Nicola M, Orlando V, Galizia S, Porfilio I, Costantini E, D'Angelo C, Ruggieri S, Biagioni S, **Gasparini C**, Tata AM. Dysregulated Homeostasis of Acetylcholine levels in immune cells of RR-multiple sclerosis patients. Int. J. Mol Sci 2016. 17(12)

**2017.**

**147.** Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfà GA, Sormani MP, Capra R, Centonze D, **Italian PML study group.** No evidence of beneficial effect of plasmapheresis in natalizumab-associated PML Neurology 2017. 88(12)

**148.** Ferraro D, Franciotta D, Bedin R, Solaro C, Cocco C, Santangelo M, Immovilli P,

Gajofatto A, Calbrese M, Di Filippo M, Orlandi R, Simone AM, Vitetta F, Capello E, Giunti D, Murialdo A, Frau J, Mariotto S, Gallina A, **Gasparini C**, Sola P. RIREMS group (Rising Italian researchers in Multiple Sclerosis).

A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. *J Neurol* 2017. 264 (5):973 – 978

**149.** Tortorella C, Dirienzo V, Ruggieri M, Zoccolella S, Mastropasqua M, D’Onghia M, Paolicelli D, Cuonzo FD, **Gasparini C**, Trojano M.

Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.

*Mult scler.* 2017

**150.** Annovazzi P, Bertolotto A, Brescia Morra V, **Gasparini C**, Montanari E, Navarra P, Patti F, Sormani MP, Ghezzi A.

A Comprehensive Review on Copemyl®.

*Neurol Ther.* 2017

**151.** Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB, Brescia Morra V, Costantino G, Cavalla P, Centonze D, Comi G, Cottone S, Danni MC, Francia A, Gajofatto A, **Gasparini C**, Zaffaroni M, Petrucci L, Signoriello E, Maniscalco GT, Spinicci G, Matta M, Mirabella M, Pedà G, Castelli L, Rovaris M, Sessa E, Spitaleri D, Paolicelli D, Granata A, Zappia M, Patti F; SA.FE. study group.

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).

*PLoS One.* 2017

**152.** Colais P, Agabiti N, Davoli M, Buttari F, Centonze D, De Fino C, Di Folco M, Filippini G, Francia A, Galgani S, **Gasparini C**, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Bargagli A; Multiple Sclerosis Study Group, Lazio Region.

Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy.

*Neuroepidemiology.* 2017

**153.** Ruggieri S, Tortorella C, **Gasparini C**.

Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis.

*Expert Rev Neurother.* 2017

**154.** Amadio S, Parisi C, Piras E, Fabbrizio P, Apolloni S, Montilli C, Luchetti S, Ruggieri S, **Gasparini C**, Laghi-Pasini F, Battistini L, Volonté C.

Modulation of P2X7 Receptor during Inflammation in Multiple Sclerosis.

*Front Immunol.* 2017

**155.** Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, **Gasparini C**, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA.

Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.

*Lancet Neurol.* 2017

**2018.**

**156.** Hagens MH, Burggraaff J, Kilsdonk ID, Ruggieri S, Collorone S, Cortese R, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Wuerfel J, Ciccarelli O, **Gasperini C**, Lukas C, Rovira A, Barkhof F, Wattjes MP; MAGNIMS Study Group.

Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.  
Mult Scler. 2018

**157.** Eshaghi A, Prados F, Brownlee W, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, **Gasperini C**, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group.

Deep grey matter volume loss drives disability worsening in multiple sclerosis.  
Ann Neurol. 2018

**158.** Reale M, Costantini E, Di Nicola M, D'Angelo C, Franchi S, D'Aurora M, Di Bari M, Orlando V, Galizia S, Ruggieri S, Stuppia L, **Gasperini C**, Tata AM, Gatta V.

Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation.  
Sci Rep. 2018

**159.** Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.  
Neurology. 2018

**160.** Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.  
Neurology. 2018

**161.** Sambucci M, Gargano F, De Rosa V, De Bardi M, Picozza M, Placido R, Ruggieri S, Capone A, **Gasperini C**, Matarese G, Battistini L, Borsellino G.

FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis.  
Sci Rep. 2018

**162.** Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, **Gasperini C**, Sastre-Garriga J, Evangelou N, Palace J; MAGNIMS study group.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics

Nat Rev Neurol. 2018.

**163.** Lanzillo R, Prosperini L, **Gasparini C**, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group. A multicentre observational analysis of Persistence to Treatment in the new multiple sclerosis era: the RESPECT study. J Neurol. 2018

**164.** Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M, Tur C, De Angelis F, Cawley N, Brownlee WJ, De Stefano N, Laura Stromillo M, Battaglini M, Ruggieri S, **Gasparini C**, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Geurts JJG, Vrenken H, Wottschel V, Leurs CE, Uitdehaag B, Pirpamer L, Enzinger C, Ourselin S, Gandini Wheeler-Kingshott CA, Chard D, Thompson AJ, Barkhof F, Alexander DC, Ciccarelli O; MAGNIMS study group. Progression of regional grey matter atrophy in multiple sclerosis. Brain 2018

Claudio Gasparini





## **Azienda Ospedaliera S Camillo Forlanini Multiple Sclerosis Center**

**Roma 8 aprile 2019**

Il sottoscritto Claudio Gasperini dichiara non deve avere subito sentenze di condanna passate in giudicato in relazione all'attività della Società, e la insussistenza di situazioni o l'esercizio di attività o partecipazione ad esse, che possano creare cause di conflitto d'interesse con la Società;

Prof. Claudio Gasperini

*Claudio Gasperini*



## **Azienda Ospedaliera S Camillo Forlanini Multiple Sclerosis Center**

**Roma 8 aprile 2019**

Il sottoscritto Claudio Gasperini dichiara di voler candidarsi per la elezione del consiglio direttivo della SNO (Disciplina Neurologia).

Gli obiettivi che ritengo di portare avanti possono essere così riassunti:

1. Coordinamento del gruppo di studio Sclerosi Multipla e potenziamento delle attività ad esse correlate
2. Coordinamento con il gruppo di studio della Neurologia di Emergenza potenziando la collaborazione e le attività ad esso correlate
3. Programmazione di attività scientifiche in ambito regionale e nazionale
4. Collaborazione nella stesura di linee guida
4. Collaborazione con tutti gli altri membri del consiglio direttivo per le attività scientifiche e istituzionali finalizzate alla promozione del ruolo della nostra Società in ambito accademico e istituzionale

Prof. Claudio Gasperini

A handwritten signature in black ink that reads 'Claudio Gasperini'.